Arcturus Therapeutics
ARCT
43 hedge funds and large institutions have $43M invested in Arcturus Therapeutics in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 8 closing their positions.
194% more call options, than puts
Call options by funds: $2.14M | Put options by funds: $727K
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
4% less funds holding
Funds holding: 45 → 43 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
53% less capital invested
Capital invested by funds: $91.2M → $43M (-$48.1M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$2.26M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$1.83M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$1.62M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.46M |
| 5 |
RA
Royce & Associates
New York
|
+$637K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.35M |
| 2 |
DM
Deerfield Management
New York
|
-$4.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$4.62M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.56M |
| 5 |
JG
Jefferies Group
New York
|
-$500K |
ARCT Hedge Fund Activity: Q3 2016 in Review
43 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2016, worth a combined $43M — down 53% from $91.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ARCT and 6 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was Broadfin Capital, adding an estimated $2.26M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.35M sold.
- 43 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2016, down from 45 in Q2 2016.
- Funds reported $43M of Arcturus Therapeutics stock for Q3 2016, down 53% quarter-over-quarter.
- 6 funds opened new Arcturus Therapeutics positions in Q3 2016 and 8 closed out, a net change of -2 holders.
- The largest Arcturus Therapeutics buyer in Q3 2016 was Broadfin Capital, an estimated $2.26M added.
- The largest Arcturus Therapeutics seller in Q3 2016 was Great Point Partners, an estimated $6.35M sold.
Based on aggregated 13F filings for Q3 2016.